Camilla joined the board of Hoba Therapeutics in 2021. She brings more than a decade of international business development experience from early academic start-up to industry. Camilla is currently a principal at Novo Holdings, where she is responsible for company creation and early investments, in addition to investments through the REPAIR Impact fund. Camilla also serves as a director on the Board of Directors of Limmatech and Centauri Therapeutics, and as an observer on the Boards of Directors for Muna and Hemab. Camilla has a PhD in Medicinal Chemistry and a Master of Pharmacy degree from Copenhagen University.